Pages that link to "Q40684099"

The following pages link to Effects on RNA interference in gene expression (RNAi) in cultured mammalian cells of mismatches and the introduction of chemical modifications at the 3'-ends of siRNAs (Q40684099):

Displaying 43 items.

• Crystal structure, stability and in vitro RNAi activity of oligoribonucleotides containing the ribo-difluorotoluyl nucleotide: insights into substrate requirements by the human RISC Ago2 enzyme (Q27648323) (← links)
• Trafficking of tachykinin neurokinin 3 receptor to nuclei of neurons in the paraventricular nucleus of the hypothalamus following osmotic challenge (Q28564887) (← links)
• Characterization of transgenic zebrafish lines that express GFP in the retina, pineal gland, olfactory bulb, hatching gland, and optic tectum (Q30540414) (← links)
• Inhibition of coxsackievirus B3 replication by small interfering RNAs requires perfect sequence match in the central region of the viral positive strand (Q33781261) (← links)
• Lentiviral-mediated delivery of siRNAs for antiviral therapy (Q34482299) (← links)
• siRNAmod: A database of experimentally validated chemically modified siRNAs (Q34511095) (← links)
• RNAi as a gene therapy approach (Q35164788) (← links)
• The activity of siRNA in mammalian cells is related to structural target accessibility: a comparison with antisense oligonucleotides (Q35222789) (← links)
• Potentials for RNAi in sarcoma research and therapy: Ewing's sarcoma as a model. (Q35561604) (← links)
• Pharmaceutical prospects for RNA interference. (Q35675699) (← links)
• Control of nonsegmented negative-strand RNA virus replication by siRNA. (Q35739895) (← links)
• The use of gene therapy in cancer research and treatment (Q35904008) (← links)
• Development of gene-specific double-stranded RNA drugs (Q35932393) (← links)
• Development of Therapeutic-Grade Small Interfering RNAs by Chemical Engineering (Q36174842) (← links)
• Silence of the transcripts: RNA interference in medicine (Q36199753) (← links)
• RNA knockdown as a potential therapeutic strategy in Parkinson's disease. (Q36305419) (← links)
• Antiviral applications of RNAi for coronavirus (Q36376425) (← links)
• Antiviral applications of RNAi. (Q36440297) (← links)
• Molecular design and delivery of siRNA. (Q36633638) (← links)
• Alternative approaches for efficient inhibition of hepatitis C virus RNA replication by small interfering RNAs (Q37010585) (← links)
• Small interfering RNA targeting Fas protects mice against renal ischemia-reperfusion injury. (Q37571732) (← links)
• Chemical modification of siRNA. (Q37655882) (← links)
• Exploring chemical modifications for siRNA therapeutics: a structural and functional outlook (Q37665372) (← links)
• RNA interference therapy for glioblastoma (Q37736499) (← links)
• Chemical Modification of Small Interfering RNA (Q37856843) (← links)
• Complexity in the therapeutic delivery of RNAi medicines: an analytical challenge. (Q38221915) (← links)
• Regulation and functional role of the Runt-related transcription factor-2 in pancreatic cancer (Q38298230) (← links)
• Transgenic RNAi-mediated reduction of MSY2 in mouse oocytes results in reduced fertility (Q38343445) (← links)
• Novel Oligonucleotides Containing Two 3′-Ends Complementary to Target mRNA Show Optimal Gene-Silencing Activity (Q39564306) (← links)
• Effect of north bicyclo[3.1.0]hexane 2'-deoxy-pseudosugars on RNA interference: a novel class of siRNA modification. (Q39765698) (← links)
• Relative gene-silencing efficiencies of small interfering RNAs targeting sense and antisense transcripts from the same genetic locus (Q39984813) (← links)
• Computational design of antiviral RNA interference strategies that resist human immunodeficiency virus escape. (Q40454547) (← links)
• Paradigms for conditional expression of RNA interference molecules for use against viral targets. (Q40472917) (← links)
• Effect of base modifications on structure, thermodynamic stability, and gene silencing activity of short interfering RNA. (Q42046598) (← links)
• RNA interference in mammalia cells by RNA-3'-PNA chimeras (Q42048191) (← links)
• Selection of predicted siRNA as potential antiviral therapeutic agent against influenza virus (Q42175054) (← links)
• Evidence that TRPC1 (transient receptor potential canonical 1) forms a Ca2+-permeable channel linked to the regulation of cell volume in liver cells obtained using small interfering RNA targeted against TRPC1 (Q43002992) (← links)
• Vector-based RNAi, a novel tool for isoform-specific knock-down of VEGF and anti-angiogenesis gene therapy of cancer (Q45861347) (← links)
• RNA interference for glioblastoma therapy: Innovation ladder from the bench to clinical trials (Q45871459) (← links)
• Use of recombinant calpain-2 siRNA adenovirus to assess calpain-2 modulation of lung endothelial cell migration and proliferation (Q51190794) (← links)
• Preferential silencing of a common dominant rhodopsin mutation does not inhibit retinal degeneration in a transgenic model (Q58413953) (← links)
• Silencing activity of 2′-O-methyl modified anti-MDR1 siRNAs with mismatches in the central part of the duplexes (Q59235934) (← links)
• RNA interference in vivo: toward synthetic small inhibitory RNA-based therapeutics (Q81255508) (← links)